Nov 15, 2022· Comment from Consumer Healthcare Products Association (CHPA)· FDA-2021-D-0528-0008
Please accept this document with one minor correction in place of our original submission. Thank you. CHPA
FDANonrulemakingFDA-2021-D-0528
Quantifying Sodium, Potassium, and Phosphorus in Labeling for Human Over-the-Counter and Prescription Drug Products; Draft Guidance for Industry; Availability
RIN
—
Last modified
Nov 15, 2022
Comment window
closed 1358d ago
Consumer Healthcare Products Association filings
2
Activity
Consumer Healthcare Products Association filed 2 comments on this docket between Nov 7, 2022 and Nov 15, 2022. 0 other organizations filed here. The comment window closed 1358d ago.
What Consumer Healthcare Products Association filed (2)
Nov 7, 2022· Comment from Consumer Healthcare Products Association (CHPA)· FDA-2021-D-0528-0003
The attached comments are submitted on behalf of the Consumer Healthcare Products Association on Monday, November 7, 2022.
Abstract
No abstract recorded.
View on regulations.gov →Co-filers (0)
See everyone who commented →- Consumer Healthcare Products AssociationTHIS ORG2 filings · confidence 97%